布罗索尤单抗治疗改善X连锁低磷性佝偻病成人口腔健康
该单中心回顾性分析纳入44例接受至少6个月牙科监测的X连锁低磷性佝偻病成人患者,比较无治疗、传统治疗(口服磷酸盐和活性维生素D)与布罗索尤单抗治疗期间的口腔健康状况及牙髓感染发生率。结果显示,与传统治疗相比布罗索尤单抗治疗期间感染减少86.4%,而传统治疗期间减少55.9%(与无治疗期相比,P<.0001);同一患者内比较,布罗索尤单抗治疗期感染发生率为每月0.006次,无治疗期为每月0.09次(P<.01)。
要点
- 布罗索尤单抗治疗期牙髓感染较无治疗期减少86.4%,传统治疗期减少55.9%(P<.0001)。
- 同一患者内比较,布罗索尤单抗治疗期感染发生率为每月0.006次,无治疗期为每月0.09次(P<.01)。
- 成人XLH患者口腔健康随成年后接受XLH治疗时间占比不同而变化,随访期间牙科感染发生率受治疗类型影响。
核心结论
- 接受布罗索尤单抗治疗的XLH成人患者在牙科随访期间发生的牙髓感染少于未治疗或接受传统治疗的患者。
研究设计与样本
- 单中心回顾性分析,纳入44例接受至少6个月牙科监测的XLH成人患者,按治疗方式(无治疗、传统治疗或布罗索尤单抗)比较口腔健康及牙髓感染发生率。
主要发现
- 与无治疗期相比,传统治疗期间感染减少55.9%,布罗索尤单抗治疗期间感染减少86.4%(P<.0001)。
- 同一患者内比较,布罗索尤单抗治疗期感染发生率为每月0.006次,无治疗期为每月0.09次(P<.01)。
- 口腔健康随成年后接受XLH治疗时间占比不同而变化,随访期间牙科感染发生率受治疗类型影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: X-linked hypophosphatemia (XLH) is a rare genetic bone disease affecting both children and adults, with oral manifestations such as spontaneous dental infections. The main treatments for XLH are conventional treatment (CT) with oral phosphate salts and active vitamin D supplementation and burosumab, an antibody targeting fibroblast growth factor 23. While the beneficial effect of CT on oral manifestations is established, the effect of burosumab on oral health is unknown, especially in adults. OBJECTIVE: We aimed to compare the oral health (number of missing or endodontically treated teeth and presence of periodontal disease) and incidence of endodontic infections of adult patients with XLH according to their treatment's modalities (no treatment, CT, or burosumab). METHODS: This was achieved through a single-center, retrospective analysis of oral health data from 44 patients who had undergone dental monitoring for at least 6 months. RESULTS: Oral health varied according to the proportion of their adult life spent under treatment for XLH, and the incidence of dental infections during follow-up was influenced by the type of treatment received. There was a 55.9% reduction of infections during CT and an 86.4% reduction during burosumab treatment compared to periods with no treatment (P < .0001). Comparing treatment and nontreatment periods within the same patient showed a strong association between burosumab treatment and decreased infection incidence (.006 vs .09 infection per month, P < .01). CONCLUSION: We observed that adults with XLH treated with burosumab developed fewer endodontic infections during dental follow-up than patients who were untreated or received CT.
引用
- Hervé A, Gadion M, Herrou J, et al. Improved Oral Health in Adults With X-Linked Hypophosphatemia Treated With Burosumab. J Clin Endocrinol Metab. 2025. PMID: 38864457. doi:10.1210/clinem/dgae398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。